Pharmaceutical UK-based Phytopharm (LSE: PYM: London Stock Exchange), ahead of its annual general meeting today (March 27) stated that, following the disappointing Phase II clinical trial with its Parkinson's disease drug candidate Cogane (PYM 50028), it has initiated an update on the on-going strategic review of the company's options, which could include a merger or acquisition of the firm. 27 March 2013